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sensory neuropathies (HMSN; for review, see Dyck etFrank Zimmermann,* Josef P. Magyar,³
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CMT is one of the most common genetic diseases, withHans-Michael Meinck,§ Ueli Suter,³
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which the primary genetic defect resides in SchwannUniversity of Heidelberg
cells (CMT1). This clinical entity has been further subdi-D-69120 Heidelberg
vided by linkage to chromosomes 17 (CMT type 1A),Federal Republic of Germany
chromosome 1 (CMT1B),and theX chromosome (CMTX)²Department of Veterinary Clinical Studies
(for review, see Patel and Lupski, 1994). About 70%±Glasgow University
80% of all patients are affected by CMT1A, an autoso-Glasgow G61 1QH
mal-dominant form, genetically linked to the regionUnited Kingdom
17p11.2 (Wise et al., 1993; Ionasescu, 1995).³Department of Cell Biology
Clinically, CMT1A is characterized by slowly progres-Swiss Federal Institute of Technology
sive muscle weakness and loss of proprioception, caus-ETH-Hoenggerberg
ing gait abnormalities and peroneal muscular atrophyCH-8093 ZuÈ rich
in the second to third decade of life (Dyck et al., 1993).Switzerland
The severity of the disease is variable, but severely re-§Department of Neurology
duced nerve conduction velocity (NCV) of both motorUniversity of Heidelberg
and sensory fibers are a regular finding (Nicholson,
D-69120 Heidelberg
1991). Histologically, a progressive demyelination of pe-
Federal Republic of Germany
ripheral nerves is associated with Schwann cell hyper-
trophy, leading to the characteristic formation of onion
bulb structures and collagen depositions.
A major step in unravelling the genetic basis of CMTSummary
was the identification of an intrachromosomal duplica-
tion on chromosome 17, associated with CMT1A (LupskiCharcot-Marie-Tooth disease (CMT) is the most com-
et al., 1991; Raeymakers et al., 1991). The duplicationmon inherited neuropathy in humans and has been
of approximately 1.5 3 106 bp DNA in about 90% ofassociated with a partial duplication of chromosome
clinically diagnosed patients (Roa et al., 1993b) sup-17 (CMT type 1A). We have generated a transgenic
ported a novel gene-dosage model that assumes thatrat model of this disease and provide experimental
overexpression of one or more genes contained in the
evidence that CMT1A is caused by increased expres-
duplicated region of 17p11.2 underlies CMT1A.
sion of the gene for peripheral myelin protein-22 The gene for peripheral myelin protein 22 (PMP22) has
(PMP22, gas-3). PMP22-transgenic rats develop gait emerged as a particularly attractive candidate disease
abnormalities caused by a peripheral hypomyelina- gene because it isexpressed in Schwanncells and maps
tion, Schwann cell hypertrophy (onion bulb formation), to chromosome 17p11.2 (Patel et al., 1992; Timmerman
and muscle weakness. Reduced nerve conduction ve- et al., 1992; Matsunami et al., 1992; Valentijn et al.,
locities closely resemble recordings in human patients 1992a). Moreover, point mutations in PMP22 cause dys-
with CMT1A. When bred to homozygosity, transgenic myelination in the Trembler mouse (Suter et al., 1992)
animals completely fail to elaborate myelin. We antici- and CMT1A in a small subset of families (Valentijn et
pate that the CMT rat model will facilitate the identifi- al., 1992b; Roa et al., 1993b, 1993c). In accordance with
cation of a cellular disease mechanism and serve in a gene dosage model, increased steady-state levels of
the evaluation of potential treatment strategies. PMP22 mRNA in some CMT1A nerve biopsies have been
reported (Yoshikawa et al., 1994), but the significance
of these findings has been questioned by others (Hane-
Introduction mann et al., 1994; Kamholz et al., 1994).
PMP22 is a small, integral membrane protein ex-
Myelin formation by glial cells and its maintenance in pressedmainly bymyelin-formingSchwann cells (Snipes
the adult nervous system requires the coordinated ex- et al., 1992). With four predicted transmembrane do-
pression of a group of membrane-associated proteins mains, PMP22 belongs to a diverse group of four-helix
that become major structural components of the myelin bundle proteins localized in myelin (Snipes and Suter,
sheath (for review, see Lemke, 1988; Hudson, 1990; 1995b). Although PMP22 was identified as a peripheral
Nave, 1995; Snipes and Suter, 1995a). The function of myelin protein that is downregulated in Schwann cells
these proteins for the architecture of compacted myelin after injury-induced denervation (Kitamura et al., 1976;
has been studied intensively with the help of naturally Spreyer et al., 1991; Welcher et al., 1991), PMP22 ex-
occurring and artificially generated mutants. pression is not specific to PNS myelin. In fact, PMP22
In humans, the genetically determined failure to as- is the rat homolog of gas3, one of several growth arrest-
specific genes of unknown function, originally clonedsembleor maintain PNS myelin defines a heterogeneous
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Figure 1. Generation of PMP22-Transgenic
Rats
(A) Cosmid-derived NruI fragment of the mu-
rine PMP22 gene (top row, thin line) with the
complete murine transcriptionunit (exons 1A±
5). Flanking vector sequences are shown as
open boxes.The exact locationof exons 3 and
4 has not been determined; the position of a
genomic fragment (59 probe) used for library
screening and Southern blot analysis is indi-
cated. Shownbelow isthe exon-intron organi-
zation ofPMP22 (intron sizes not to scale) with
the approximate position of primers used for
RT-PCR (primer pair AB) and genotyping
(primer pair CD). Most PMP22 transcripts in
Schwann cells contain exon 1A (Suter et al.,
1994). Indicated are restriction sites NruI (Nr),
KpnI (K), BamHI (B), SalI (S), PstI (P; in mouse
only), and NotI (N; in rat only).
(B)Routine identificationoftransgenicratsuti-
lizes mouse-specific PCR primers from exon
5. Shown is a genotype analysis from a repre-
sentative F1 litter. Presence of a 501 bp PCR
product correlates with a visible phenotype
(1) at 2.5 months of age.
(C) Southern blot analysis of PMP22-trans-
genic rats (tg1, tg2 from B; tg5) and a nontransgenic littermate (wt1 from (B) using the mouse-specific 59 probe. In BamHI-digested rat DNA (10
mg) of tail biopsies, a 2.3 kb fragment is specific for the murine PMP22 transgene, as confirmed by the presence of the same fragment in normal
mouse genomic DNA (lane M, 15 mg). A homozygous rat in the F2 generation (hz1) has twice the transgene dosage of a heterozygous littermate
(tg5), when normalized to the signal of an internal control gene (data not shown).
from murine NIH 3T3 cells (Schneider et al., 1988; Manfi- of exon 5 (Figure 1A). DNA-microinjection of fertilized
Sprague-Dawley rat oocytes resulted in the generationolettietal.,1990).PMP22gene transcriptshavealso been
detected in spinal cord motorneurons and in several of one founder male that was able to breed normally
and was used to set up a line of PMP22-transgenic rats.embryonic and adult tissues outside the nervous system
(Baechner et al., 1995; Parmantier et al., 1995). The nor- To estimate the transgene copy number, we com-
pared by Southern blot analysis genomic DNA frommal function of PMP22 is not known. In mutant mice that
completely lack PMP22 expression, PNS myelination transgenic rats with a series of mouse genomic stan-
dards, utilizing a mouse-specific probe of the PMP22is delayed and followed by focal hypermyelination and
myelin degeneration (Adlkofer et al., 1995). Taken to- gene (data not shown). Based on the phosphoimager
analysis of hybridization signals, we estimated that threegether, the available genetic data have demonstrated
that PMP22 is required for normal Schwann cell differen- copies of the microinjected DNA fragment constitute
the PMP22 transgene. For all subsequent genotype de-tiation and overall myelin stability. Although PMP22 is
expressed outside the nervous system, the reported terminations, we employed a PCR-based assay, and the
amplification of a 501 bp genomic fragment with mouse-abnormalities in the known PMP22 mutants are re-
stricted to Schwann cells specific primers (Figures 1B and 1C).
To investigate whether dosage increase is sufficient
to turn the wild-type PMP22 gene into a disease gene, Peripheral Neuropathy in
we have generated a transgenic rodent model. Here we PMP22-Transgenic Rats
show by a combination of genetic, behavioral, morpho- At about 2 months of age, the founder male displayed
logical, and electrophysiological criteria that PMP22- an unsteadiness of gait, reminiscent of the 'steppage'
overexpressing rats develop a peripheral neuropathy gait in CMT patients. Tremor or seizures were absent. In
that closely mimics autosomal-dominant CMT1A. The the progeny, 43 of 86 animals showed a similar unsteady
CMT-rat serves as a novel tool to investigate the behav- gait,correlatingwith a presence ofthePMP22 transgene.
ior of PMP22 overexpressing Schwann cells in vivo and A loss of muscle strength became obvious when rats
in vitro. tried to right up at the cage wall (Figure 2A). When walk-
ing over a flat surface in a straight line, transgenic rats
Results moved clumsily and most displayed a notable outward
positioning of their hind feet (Figure 2B).
Despite some interindividual variations in phenotype,Generation of PMP22-Transgenic Rats
We attempted to increase the PMP22 gene dosage in transgenic rats (n 5 23) failed uniformly in a simple
behavioral assay of motor performance and gripthe rat that is the preferred model system for studying
Schwann cell development in vivo and in vitro. The wild- strength, the bar test (Figure 3A). When placed on a
round horizontal bar (diameter 1.5 cm), wild-type ratstype gene was cloned from a 129SV mouse cosmid
genomic library. A 43 kb restriction fragment that con- learned, within a set of six trials, to balance and support
their weight. In contrast, transgenic rats were unable totained the PMP22 transcription unit was excised, includ-
ing 7 kb upstream of exon 1A and 4 kb downstream stay on the barand droppedwithin the first minute. While
CMT-Rat Model
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Figure 2. Peripheral Neuropathy in PMP22-
Transgenic Rats
(A) At 2 months of age, heterozygous trans-
genic rats develop an unsteadygait and signs
of muscle weakness. When righting up, they
often fail to sustain their body weight on the
stretched hind limbs. Muscle atrophy of the
hindlimbs is more obvious in older rats.
(B) Footprint analysis. Heterozygous rats
show clumsiness in walking. A slight outward
positioning of the hind paws can be detected
in a footprint analysis, with the pattern of the
wild type (left) slightly different from the
transgenic (right). Note the increased angle
pointing away from the forward direction of
the rat (green lines mark the wild-type pattern
in both panels).
(C) Homozygous PMP22-transgenic rats are
more severely affected than heterozygous
rats, retarded in growth, and they never learn
to control limb movements. Shown is a 4
week-old rat with episodes of spasticity and
paraplegia.
this test served as a reliable indicator of transgenicity for axonal degeneration in PMP22-transgenic rats (see be-
younger rats, older animals had also difficulties because low), EMG recordings from the plantar foot muscles
of their increased body weight. To measure the motor disclosed moderate to abundant fibrillation potentials
performance of 11 month-old rats, we chose the rotarod and positive sharp waves (Figure 4B), suggesting a par-
test for moving animals. Rats (n 5 9) were placed on tial muscle denervation.
a 10 cm wide, horizontal rod (diameter 10 cm), with
shieldings on each side. After 30 s at rest, the rod was Peripheral Hypomyelination of
rotated slowly at one round per min, and this speed was PMP22-Transgenic Rats
doubled every minute (Figure 3B). The average time that A morphological analysis demonstrated the loss of my-
rats were able to stay on the rod differed significantly elin in peripheral and cranial nerves. In cross sections
between PMP22-transgenic rats and age-matched wild- of sciatic nerves, many axons had thin or absent myelin
type rats, also demonstrating a deficit of motor perfor- sheaths (Figures 5A±5C and 6A). The extent of hypomy-
mance in older animals. elination differed between individuals and correlated
with the visible phenotype. At 2.5 months of age, very
occasional supernumerary Schwann cell processes andReduced Nerve Conduction Velocity
basal laminae surrounded hypomyelinated or amyelin-The hallmark of CMT1 is the reduction of nerve-conduc-
ated axons (early onion bulbs) (Figure 6A). By 6 monthstion velocities (NCV) in peripheral nerves. PMP22-trans-
of age, onion bulbs were extensive (Figures 5A, 6B, andgenic rats were analyzed at 2.5 months of age and
6C). The severity of abnormalities was greater in theshowed a substantial decrease of the conductive prop-
ventral nerve roots compared with dorsal roots (Figureserties of both motor and sensory nerves (Figure 4A;
5E and 5F) or the distal sciatic and tibial nerves. TheTable 1). Compound motor action potential (CMAP) la-
ventral/dorsal difference was still reflected in the periph-tencies were increased, resulting in a motor nerve con-
ery, as nerves that arepredominantly motor (e.g., branchduction velocity of 14.7 (6 5.1) m/s in transgenic rats,
to medial gastrocnemius) were more severely affectedcompared with 36.4 (6 2.5) m/s in wild-type littermates.
than those that are predominantly sensory (e.g., distalIncreases in latency were also found for minor dis-
tibial nerves; data not shown).charges of antidromically activated motorneurons
In general, hypomyelination was more marked in(F-waves). In addition to slowing of the NCV, CMAP
larger diameter fibers (presumably motor), while manyamplitude from distal stimulation were reduced. Sensory
smaller fibers had sheaths of normal or even increasednerve action potentials (SNAPs) could be recorded in
thickness (Figures 5C and 6B). The myelin deficit wastwo rats, and NCV was reduced to 14.9 (6 7.2) m/s in
variable along individual fibers (segmental demyelin-transgenics from 34.5 (6 4.0) m/s in the wild type (Table
ation), even within a single internode (Figure 5G). Myelin1). Thus, reductions of NCV were similar to the findings
sheaths were well compacted with normal periodicity.in patients with CMT1A (Kaku et al., 1993). Recordings
Myelin debris was seen only occasionally in Schwannmade at a distance of 40 mm from the stimulating elec-
cells, and reactive macrophages were not a feature. Thetrode showed characteristic desynchronization of
amount of endoneurial collagen was increased. AxonalCMAP (polyphasia) in transgenic rats, which represent
degeneration was a rare finding involving less than 1%physiological signs of demyelination (Figure 4A). Al-
though there was minimal morphological evidence of of fibers. Neuronal cell bodies in the dorsal root ganglia
Neuron
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Table 1. Reduced Nerve Conduction Velocities in PMP22-
Transgenic Rats
Wild type PMP22-Transgenic
Motor latency (ms)
Proximal stimulation 3.3 (6 0.1) 10.3 (6 4.5)a
Distal stimulation 1.8 (6 0.2) 5.3 (6 1.8)a
Motor conduction
velocity (m/s) 36.4 (6 2.5) 14.7 (6 5.1)a
CMAP amplitude (mV)
Proximal stimulation 6.4 (6 2.0) 0.7 (6 0.4)a
Distal stimulation 11.3 (6 4.0) 1.4 (6 1.2)a
Sensory latency (ms)
Distal stimulation 1.8 (6 0.2) 4.6 (6 2.2; n 5 2)b
Sensory conduction
velocity (m/s) 34.5 (6 4.0) 14.9 (6 7.2; n 5 2)b
SNAP amplitude (mV) 5.7 (6 3.8) 2.0 (o; n 5 2)b
Electrophysiological recordings are from 2.5 month-old heterozy-
gous transgenic rats and agematched nontransgenic controls. All
data are expressed as mean 6 SD. Sample size is n 5 5 (PMP22-
transgenics) and n 5 3 (age-matched controls), except where indi-
cated. All differences between wild type and transgenics are signifi-
cant (a p , 0.01; b p , 0.021; by two-tailed Mann-Whitney-U test).
and ventral horn were unremarkable and no abnormali-
ties were detected in CNS fibers (data not shown). Taken
together, the morphological abnormalities of PMP22-
transgenic rats closely resemble thepathology of humanFigure 3. Decreased Motor Performance of Adult PMP22-Trans-
genic Rats patients with CMT1A.
(A) In the bar test, the time (in seconds 6 SEM) was recorded, in
which 2.5 month-old heterozygous rats were able to stay on a 50 Homozygous PMP22-Transgenic Rats
cm long rod (diameter 1.5 cm). In six consecutive trials, wild-type Remain Amyelinated
rats (n 5 8) learned to balance, whereas PMP22-transgenic rats Homozygote PMP22-transgenic rats displayed a more(n 5 13) showed significant deficits. Maximal trial length was 300
severe and uniform phenotype. They never developeds. Differences are significant from the fourth trial on (p < 0.0025;
a coordinated gait and were paralyzed at 4 weeks ofStudent's t-test).
(B) A rotarod test demonstrates motor deficits of older rats (11 age (Figure 2C). Occasionally, spasticity and seizures
months). In a series of 6 consecutive trials, the cumulative time (in were observed. Symptoms were progressive and the
seconds 6 SEM) was scored in which animals were able to stay on animals became severely retarded in development.
a slowly rotating roller (diameter 10 cm). After 30 s at rest, rotating Many homozygotes died before 1 month of age or had
speed (starting at 1 rpm) was increased in 60 s intervals to 2, 4, 8,
to be sacrificed.12, 16, and 20 rpm (indicated on the right). None of the PMP22-
By light and electron microscopic analysis, homozy-transgenic rats (n 5 6) was able to stay at 12 rpm (age-matched
wild-type rats 20 rpm; n 5 3). Hold time was significantly lower in gous rats were completely lackingPNS myelin. Schwann
transgenic animals (p < 0.05; Mann-Whitney-U-test) in all trials ex- cells, which were increased in number, had segregated
cept trial 3 (p < 0.071). with axons in a normal 1:1 ratio and formed a basal
lamina, but failed to assemble myelin (Figures 5D and
Figure 4. Sciatic Nerve Conduction Veloci-
ties and EMG Recordings
(A) Representative traces of sciatic nerve
compound motor action potentials (CMAP)
recorded from a foot muscle after proximal
and distal stimulation. Compared to 2.5
month-old wild-type rats (left), age-matched
PMP22-transgenics show significantly in-
creased latencies (right). Note the different
horizontal and vertical calibration in the top
panels. Drop in amplitude and marked tem-
poral desynchronisation suggest hypomy-
elination. Numeric data are summarized in
Table 1. The reduction of NCV closely resem-
bles recordings in human patients with
CMT1A.
(B) Representative EMG traces from a foot
muscle of wild-type (left) and PMP22-trans-
genic rats (right). Note the absence of sponta-
neous electrical activity in normally innervated muscle of the wild type, and the spontaneous activity in PMP22-transgenic rats. The latter
serves as an indirect but sensitive indicator of muscle fiber denervation.
CMT-Rat Model
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Figure 5. Peripheral Hypomyelination in
PMP22-Transgenic Rats
(A) Resin sections (1 mm) of sciatic nerve from
an adult wild type showing that the thickness
of normal myelin sheaths is proportionate to
axon size.
(B) Heterozygous PMP22-transgenic rat of 5
weeks of age. A proportion of axons (arrows)
has no myelin sheaths, some have thin my-
elin, and in others the sheaths are of normal
thickness. All myelin-forming Schwann cells
have a 1:1 ratio with axons.
(C) Heterozygous PMP22-transgenic rat at 6
months of age. The larger diameter axons
have no myelin sheath whereas the majority
of small axons have a normal thickness of
sheath. Endoneurial collagen appears in-
creased (see also Figure 6C).
(D) Homozygous transgenic rat of 5 weeks of
age. Myelin is absent and endoneurial colla-
gen and Schwann cell nuclear numbers are
increased. Axons appear densely packed.
(E and F) Comparison of abnormalities in ven-
tral (E) and dorsal (F) nerve roots of a hetero-
zygous rat at 6 months of age. The ventral
roots are markedly more affected and several
onion bulbs are present (arrows).
(G) Teased fiber from sciatic nerve of a 2.5
month-old heterozygote showing a region
where myelin is absent (appearing thin and
pale between arrowheads), characteristic of
segmental demyelination. The region to the
left of this area is also thin compared with
the normal sheath to the right. Scale bar rep-
resents 30 mm (for A±G).
6D). Many Schwann cells contained small membranous rats, in agreement with data from human biopsy material
(Hanemann et al., 1994; Yoshikawa et al., 1994). Whencollections (Figure 6D), though overt myelin debris was
not seen. Supernumerary Schwann cells and onion the mean of the wild-type level (n 5 8) was defined
as 1.0 (range 0.4±1.7), overexpression in age-matchedbulbs were not present at 5 weeks of age. Endoneurial
collagen was markedly increased (Figures 5D and 6D) transgenic rats (n 5 10) ranged from 1 to 4-fold (Figure
7D). Homozygotes at the age of 4 weeks showed up toand fibroblasts frequently contained lipid droplets. No
abnormalities were detected in CNS fibers or unmyelin- 6-fold elevated mRNA levels. When P0 mRNA was used
as an internal standard, PMP22 mRNA levels were in-ated fibers of the PNS.
creased to the same extent. Interestingly, the degree of
overexpression correlated with the severity of the visualTranscriptional PMP22 Overexpression
CMT rats and their wild-type littermates were compared phenotype (Figure 7D). We specifically noted that two
transgenic rats with the lowest PMP22 mRNA level wereat both the RNA and protein levels. We used RT-PCR
to quantitate PMP22 mRNA in the sciatic nerve, and not visibly affected (but they failed in the bar test). Tran-
scriptional overexpression was also confirmed by PstInormalized results to GAPDH mRNA (Figure 7A) or to
myelin protein zero (P0) mRNA (Figure 7B). Within the and NotI restriction digests, which separated transgenic
(mouse) and endogenous (rat) PMP22 cDNA (Figure 7B).linear range of these reactions, amplification results
were reproducable with a sample to sample deviation
of <10% (data not shown). Analysis of Myelin Proteins
Western blots revealed a slight decrease of PMP22In the analysis of 18 animals (aged 2.5 months), we
noted a considerable variation in the steady-state level protein in sciatic nerve extracts from 2.5 month-old
transgenic rats (Figure 8). A similar reduction was seenof PMP22 mRNA among transgenic and nontransgenic
Neuron
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Figure 6. Electron Micrographs of Peripheral
Nerves from PMP22-Transgenic Rats
(A) Heterozygoustransgenic aged2.5months.
Axons have either disproportionately thin my-
elin sheaths (T) or no myelin sheaths (A). One
fiber is showing early onion bulb formation
(OB).
(B) Heterozygous transgenic rat at 6 months
of age. One fiber (N) has a myelin sheath of
normal thickness, whereas two small axons
show a disproportionately increased thick-
ness of myelin (I). Evident are two onion bulb
formations (OB). Unmyelinated fibers (U) are
normal.
(C) Typical onion bulb of a 6 month-old rat
showing concentric layers of Schwann cell
processes and redundant basal laminae
around a naked axon. Endoneurial collagen
is markedly increased (small arrows).
(D) Homozygous transgenic rat at 5 weeks of
age. Axons are surrounded by Schwann cell
cytoplasm, but none has a myelin sheath.
Membraneous debris (arrowhead) is present
in one cell. Unmyelinated fibers (U) are nor-
mal. All scale bars represent 2 mm.
for the myelin proteins P0 and MBP, suggesting that a morpholgy was normal (data not shown). Thus, PMP22-
transgenic Schwanncells showed no signs of prematuredeficit of these proteins reflects the hypomyelination by
the time of analysis. When the same Western blot was growth arrest (as defined by exiting the cell cycle), and
no evidence of increased apoptotic death, indicatingreprobed with an antibody against b-actin, a higher
steady-state level was detected in transgenic nerves, that the CMT1A disease mechanism is more complex
than a dysregulation of Schwann cell growth.indicating a corresponding overrepresentation of axon-
derived proteins.
Discussion
Normal Growth of Purified Schwann Cells
in Culture CMT is one of the most frequent human genetic dis-
eases, and the autosomal-dominant subtype CMT1A isRat Schwann cells that overexpress PMP22 cDNA in
vitro show impaired growth kinetics (Zoidl et al., 1995) the most prevalent form. It has been suggested that
CMT1A is caused by overexpression of one or moreand high levelPMP22 overexpression induces apoptosis
of NIH3T3 cells (Fabretti et al., 1995). We used our CMT- disease genes located in a segmentally duplicated re-
gion of 17p11.2 (Lupski et al., 1991; Raeymakers et al.,rat model, to determine whether a disease-relevant in-
crease of the PMP22 gene dosage is sufficient to alter 1991). We have proven this hypothesis directly by gener-
ating transgenic rats that overexpress the wild-typeSchwann cell growth in vitro. Schwann cells were puri-
fied from 3 day-old rats and their growth was monitored PMP22 gene. PMP22-transgenic rats develop a periph-
eral neuropathy that closely resembles CMT1A by mor-in a double-blinded study (with respect to the presence
of the PMP22 transgene). Absolute cell counts of 4 day- phological and physiological criteria.
Although we have obtained only one line of transgenicold cultures, prepared from individual transgenic rats
(n 5 6) and nontransgenic controls (n 5 11), showed no rats, we believe that the hypomyelinated phenotype is
a true model of human CMT1A. A random integrationsignificant difference (Figure 9). Also, the numberof DNA
synthesizing Schwann cells, nearly 100% as visualized artifact is unlikely to result in an autosomal-dominant
model of CMT. Moreover, high-level overexpression ofby the incorporation of BrdU, was not reduced and the
CMT-Rat Model
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Figure 7. Elevated PMP22 mRNA Levels in
Sciatic Nerves of Transgenic Rats
(A) Quantitative RT-PCR and phosphoimage
analysis was used to compare the steady-
state levels of PMP22 mRNA, relative with
GAPDH mRNA in a 2.5 month-old PMP22-
transgenic rat (right) and age-matched wild
type (left). Within the linear range of this
assay, the PMP22-specific PCR product (636
bp) is more abundant in transgenics than in
controls. GAPDH mRNA is unchanged. (B)
The amplified PMP22 cDNA (636 bp) was di-
gested with PstI and NotI, resulting in mouse-
specific fragments (570 bp and 66 bp; trans-
gene-derived) and rat-specific fragments
(480 bp and 156 bp). Shown are the 570 bp
and 480 bp fragments separated on a 5%
acrylamide gel. Lanes 1, wild type (4 weeks
of age); 2, wild type (2.5 months); 3 and 4,
heterozygous (2.5 months); 5 and 6, homozy-
gous (4 weeks). Note that PMP22 expression
is higher in 4 week-old rats. Amplification
products are from PCR cycle 21.
(C) RT-PCR analysis of PMP22 mRNA (as in
[A]) compared with P0 mRNA.
(D) Compilation of RT-PCR results from indi-
vidual rats (n 5 17). Open circles, wild type
(aged 2.5 months); filled circles, heterozygous
transgenics (2.5 months); open squares, ho-
mozygous transgenics (4 weeks). Phosphoimager readings were normalized to the average PMP22 mRNA level in the nontransgenic group
(defined as 1.0) and using GAPDH mRNA as an internal standard. The visible phenotype of PMP22-transgenic rats is indicated on the right
and ranked as: - (not obvious; bar test average <100 s), 1 (unsteady gate; bar test average < 60 s), 11 (more severe, bar test average <20
s), and 1111 (paraplegic). Bar test average of wild-type rats was 120 s (average hold time over six trials). Note that PMP22 overexpression
levels correlate with differences in visible phenotype. Overexpression of transgenic rats is significant (p<0.005; 2-tailed Mann-Whitney-U-
Test).
PMP22 in three independent lines of mice caused a the wild-type, closely resembling the changes found in
patients with CMT1 (Dyck et al., 1993; Kaku et al., 1993).congenital dysmyelination similar in phenotype to the
homozygous PMP22-transgenic rats described in this There was also marked temporal dispersion of the
evoked CMAPs, a feature typicalof peripheral demyelin-report (Magyar et al., unpublished data).
The electrophysiological hallmark of human CMT1 is ation in CMT1A. The degree of changes was rather ho-
mogenous in a given animal, but showed interindividualthe reduction of conductive properties of motor and
sensory nerves. In our rat model, the mean nerve con- variations similar to the findings in human patients.
The CMT rat allows a detailed histological analysisduction velocities were decreased to half the values of
Figure 8. Protein Analysis of Rat Sciatic
Nerves
(A) Western blot of myelin proteins, using in-
dependent preparations of sciatic nerve ex-
tracts (15 mg per lane). Lanes 1±3, transgenic
rats (2.5months); 4±6, age-matched wild type.
PMP22 (22 kDa) is reduced in transgen-
ics, correlating with a similar decrease of P0
(30 kDa) and MBP (18 kDa) due to the over-
all hypomyelination. In contrast, b-actin is
elevated. Note the increased presence
of a PMP22 immunoreactivity with 44 kDa
(marked by a triangle), possibly a protein
dimer.
(B) Silver-stained gel of total sciatic nerve
proteins (5 mg per lane) showing subtle differ-
ences in protein composition of PMP22-
transgenic nerves (lanes 1±3) and wild-type
nerves (lanes 4±6), including unidentified pro-
teins of glial or axonal origin, or both, in the
35K-40K range.
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integrity of myelin, suggesting that myelin-forming glial
cells are particularly sensitive to the overexpression of
their membrane protein genes. In this respect, we note
that the PMP22 gene is not Schwann cell-specific, but
also expressed in CNS motoneurons and a number of
tissues outside the nervous system (Parmantier et al.,
1995; Baechner et al., 1995). Nevertheless, primary
pathological changes in CMT1A patients and in this ro-
dent model appear to be restricted to peripheral myelin.
Whereas patients with a duplication of the X-linked
PLP gene have a similar clinical phenotype (Nave and
Boespflug, 1996), CMT1A patients with a duplication
of 17p11.2 can differ significantly in clinical severity,
suggesting an effect of modifier genes. However, clinical
heterogeneity of CMT1A was even reported in two pairs
of identical twins (Garcia et al., 1996). The appearance
of our PMP22-transgenic rats was likewise not uniform,
although any combination of modifier genes should be
identical. The CMT-rat model may help to identify epige-
netic factors that contribute to the clinical variability
and that could potentially lead to the development of
preventive measures.
Point mutations altering the primary structure of three
different membrane proteins, PMP22, P0, and connexin-
32, have been associated with CMT1 (Hayasaka et al.,
1993; Roa et al., 1993a; Bergoffen et al., 1993), sug-
gesting that mutant gene products and overexpression
of wild-type PMP22 share an abnormal gain-of-function
effect. However, the cellular disease mechanism re-
mains obscure, and it is unknown why only Schwann
Figure 9. Comparison of Normaland CMT Rat Schwann Cell Growth cells are vulnerable to the increased PMP22 gene
in Primary Culture
dosage.
(A) The BrdU labelling index of purified Schwann cells, maintained
In homozygote PMP22-transgenic rats, no myelin isin culture for 4 days, is the same for PMP22-transgenic (n 5 6) and
formed, and the abnormality is a congenic dysmyelina-nontransgenic (n 5 11) animals. Incorporation of BrdU by virtually
tion. In heterozygotous rats, the situation is more com-all cells demonstrates that transgenic Schwann cells have not pre-
maturely exited the cell cycle. plex. Amyelinated axons with no evidence of myelin
(B) After 4 days invitro, a complementary total cell count of individual breakdown in young rats mark a differentiation arrest,
cultures (n 5 17) revealed no statistically significant difference in and suggest that thedisease mechanisms are operating,
the absolute number of transgenic and nontransgenic Schwann
at least in part, prior to myelin assembly. In other fiberscells, and no signs of apoptotic cell death (data not shown). When
that are initially myelinated, demyelination occurs latercombined, the data indicate that increased PMP22 expression that
on, with signs of myelin breakdown. Thus, the CMT-likecauses demyelination in vivo does not reduce the growth rate of
Schwann cells in primary culture. phenotype of the rat is a complex mixture of a dysmyeli-
nation and a superimposed progressive demyelination.
The same may be true for human patients with CMT1A,
that is impossible in human patients. We observed the where a developmental analysis of biopsy material is
classical features of CMT1, a segmental demyelination difficult and usually limited to a small segment of the
associated with Schwann cell hypertrophy and onion (sensory) sural nerve. To better define the early onset
bulb formation. These abnormalities were more pro- changes, a detailed morphological analysis of multiple
nounced in the ventral roots than in the dorsal roots, developmental time points will be required.
which could explain why motor functions are generally In homozygous PMP22-transgenic rats, spasticityand
more impaired than sensory functions in patients with hind limb paralysis are lethal at about 4±6 weeks of
CMT1A. In younger rats, we also found signs of dysmye- age (the cause of death may be indirect). At this stage,
lination, which suggests that PMP22 overexpression has Schwann cells have segregated with axons in a 1:1 ratio
features of both a developmental and a degenerative but have failed to myelinate. Some cells may continue
disease. to divide as precursor cells, causing the visible Schwann
The myelin defect of PMP22-transgenic rats is remi- cell hypertrophy (data not shown). Although abnormal
niscent of a transgenic mouse model of Pelizaeus-Merz- cell death may occur in the context of this hypertrophy,
bacher disease, in which dys- and demyelination of the we have no morphological evidence of apoptosis in
CNS follow overexpression of the myelin proteolipid PMP22-transgenic rats at the ages studied.
(PLP) gene (Readhead et al., 1994; Kagawa et al., 1994). Schwann cells appear sensitive to both increase and
Thus, the CMT rat provides another example that in- decrease of PMP22 expression levels. The loss of one
creaseddosage turnsa normalgene into a disease gene. PMP22 gene copy is linked to the hereditary neuropathy,
with liability to pressure palsies (HNPP; Chance et al.,Remarkably, both examples are diseases that affect the
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using a phosphorimager (Fuji BAS 1000). In these experiments, the1993), a condition of myelin instability that can be mod-
neuron-specific enolase gene served as an internal genomic stan-elled in mice (Adlkofer et al., 1995). The complete ab-
dard, as described (Readhead et al., 1994).sence of PMP22 expression (that has not yet been de-
scribed in the human) is associated with a severe myelin Behavioral Analysis
defect in knock-out mice, caused by focal hypermyelina- All experiments were conducted before the rats were genotyped.
tion and subsequent degeneration of myelin sheaths In the standardized bar test, a round metal bar (diameter 1.5 cm,
length 50 cm) was positioned 30 cm above the cage floor. Rats(Adlkofer et al., 1995). Thus, PMP22-dependent neurop-
aged 1 month, 2.5 months, and 6 months were placed on the middleathies may present a continuum of disease expression.
of the bar. The time (in seconds) that animals remained on the barThe rodent models hold the promise that the underlying
was monitored. In a series of 6 trials per animal, a maximum of 5
cellular defect can be identified with techniques that are min per trial was allowed. The rotarod-test utilized a motor-driven
not applicable to patient biopsy material. In fact, as metal roller (10 cm diameter, 10 cm wide) flanked by two larger
DNA-based tests for CMT become routine, less human plates. Rats were placed on the roller and (after 30 s at rest) the
roller was started at 1 round per min (rpm). In 60 s intervals, thebiopsy material is available for research that may be
rotating speed was successively increased to 2, 4, 8, 12, 16, andovercome with a suitable animal model.
20 rpm. In a series of 6 trials per animal, the time (in seconds) inSciatic nerves from newborn rats are the preferred
which the rats remained on the roller was measured. Footprints
starting material for the generation of purified Schwann were taken with waterproof black ink on watercolor paper. Ink was
cell cultures that should hold the key to understanding applied to the hindpaws. Rats aged 2.5 months (5 transgenics, 5
the cellular defect caused by PMP22 overexpression. wild types) were analyzed when walking forward in a 12 cm wide
alley.We have utilized the CMT rat to test the suggestion
that PMP22 overexpression acts via a dysregulation of
ElectrophysiologySchwanncell growth that can be monitored invitro (Zoidl
After anesthesia with pentobarbital (240 mg/kg), the sciatic andet al., 1995). In these experiments, we found no support-
posterior tibial nerves were stimulated with needle electrodes in-
ive evidence that increased PMP22-gene dosage leads serted alongside the nerves at the sciatic notch and at the hock.
to slowed growth or a premature growth arrest (as de- Supramaximal square wave pulses lasting 200 ms were delivered
using a Neuromatic 2000 machine (Dantec Medizinelektronik, Et-fined by premature exiting of the cell cyle). Thus, in
tlingen, Germany). Compound muscle action potentials (CMAPs)context of the disease-relevant degree of PMP22 over-
were recorded from the intrinsic foot muscles on the plantar surfaceexpression, a growth arrest-specific function of PMP22
using a concentricneedle electrode. The latencies of CMAPs elicitedcould not be detected, at least in cultured Schwann
by stimulation at both proximal (hip) and distal (hock) sites were
cells. We also found no supportive evidence that apop- measured from the stimulus artefact to the first negative deflection.
totic cell death contributes to the neuropathy (Fabbretti Amplitudes were determined as the maximum voltage from baseline
to the negative peak. Late potentials resulting from the backfiringet al., 1995).
of antidromically activated motoneurons (F-waves) were also re-In conclusion, we anticipate that the PMP22-trans-
corded. The distance between the two sites of stimulation was mea-genic rat and the corresponding Schwann cell culture
sured alongside the skin surface with the leg fully extended, andsystem will provide a bona fide research tool for the
the conduction velocity calculated automatically. For sensory mea-
dissection of the CMT1A disease mechanism, and hope- surements, the nerve action potential was recorded from the digits
fully, for the development of therapeutic strategies. through a pair of surface electrodes.
HistologyExperimental Procedures
Rats aged 5 weeks, 2.5 months, and 6 months were perfused
through the left ventricle with saline followed by 5% glutaraldehyde/Molecular Cloning
4% paraformaldehyde in cacodylate buffer (pH 7.2). Samples wereThe PMP22 gene was isolated from a mouse SV129 cosmid library
removed from the optic nerve, cervical, thoracic, and lumbar regions(provided by Z. Dembic), using a 2 kb BamHI-EcoRI fragment (59
of the spinal cord, lumbar and brachial spinal nerve roots, cranialprobe in Figure 1A). A 43 kb genomic insert was released by NruI
nerves V and XII, and the following peripheral nerves: sciatic, tibial,digestion, purified by agarose gel electrophoresis, and isolated us-
vagus, and brachial plexus. Blocks were osmicated and processeding the Biotrap electroeluter (Schleicher and SchuÈ ll, Datteln, Ger-
routinely for resin embedding. Samples of sciatic nerves were alsomany). DNA was desalted and equilibrated in the injection buffer (5
postfixed in Dalton's chrome-osmium and processed for teasing inmM Tris±HCl [pH 7.5], 5 mM NaCl, 0.1 mM EDTA) using a Centricon
Araldite resin. Sections (1 mm) were stained with methylenblue/azure30 concentrator (Amicon Incorporated, Beverly, MA), and was ster-
II for light microscopy and 600A grids double stained for electronile-filtered with a prewashed 0.22 mm filtration unit (Millipore, Bed-
microscopy.ford, MA). DNA was diluted to 2 ng/ml and used for the generation
of transgenic rats.
RNA Analysis
Total RNA was isolated from sciatic nerves, lung, brain, liver, andTransgenic Rats
Pronuclear microinjection of fertilized rat eggs (Sprague-Dawley) kidney of 4 week-old, 2.5 month-old, and 6 month-old rats using
the guanidine thiocyanate/water-saturated phenol procedurewas carried out as described by Ganten et al. (1991). Tail biopsy
DNA (10 mg) was digested with BamHI, size separated on 0.8% (Chomczynski and Sacchi, 1987). For RT-PCR analysis, cDNA was
synthesized from total RNA using random hexamer primers andagarose gels, and Southern blots were hybridized with a mouse
PMP22 genomic probe derived from the 59 end of the injected frag- MLV reverse transcriptase (Gibco) and quantified by incorporating
trace label amounts of (32P)-dCTP. To amplify endogenous plusment. The founder male was mated to Sprague-Dawley females to
establish a transgenic line. Routine genotype analysis was per- transgene-derived PMP22 cDNA, primers were used corresponding
to exon 3 (59-CTGTACCACATCCGCCTTGG-39) and exon 5 (59-TCAformed with species-specific primers C (59-GACAAACCCCAGAC
AGTTG-39) and D (59-CCAGAAAGCC-AGGGAACTC-39), as indicated ACACGAGGCTGACGGTC-39) of the mouse PMP22 gene. To distin-
guish endogenousratmRNAfromtransgene-derived mRNA,RT-PCRin Figure 1A (mouse-specific nucleotides are underlined). PCR was
carried out in a 50 ml volume under standard conditions, resulting products weredigested with PstI (yielding mouse-specific fragments
of 66 bp and570 bp) or NotI (yielding rat-specific fragments of 156 bpin a 501 bp transgene-specific product. Homozygous transgenic
rats were obtained by brother-sister matings and identified by phe- and 480 bp), and size-separated on 5% polyacrylamide gels.
All quantitativePCRamplificationswerecarried outwith 4ngcDNA,notype and the 2-fold higher hybridization signal in Southern blots,
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100 ng of each primer, 200 mM of each desoxynucleotide-triphos- for excellent technical assistance and J. Wilbert for help with the rat
colony. An antibody against P0 was kindly provided by J. Archelosphate, 50 mM KCl, 1.5 mM MgCl2, and 2.5units Taq polymerase (Pro-
mega) in a 50 ml reaction. The reactions were trace-labeled with 32P- (WuÈ rzburg). This work was supported by grants from the Deutsche
Forschungsgemeinschaft (SFB317)to K.A.N.,theSwiss NationalSci-dCTP (3 mCi). Standard PCR parameters were denaturation at 948C
(45 s), annealing at 558C (60 s), and extension at 728C (60 s). PCR ence Foundation to U. S., and the Multiple Sclerosis Society of Scot-
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the coamplified cDNA fragments (Kodak X-AR film). Radioactivity of Schwab forhelpfuldiscussionsandcritical readingof themanuscript.
The costs of publication of this article were defrayed in part by thethe bands was quantified with a phosphorimager (Fuji BAS 1000) and
background values weresubtracted. A cDNAfragment of the ubiqui- payment of page charges. This article must therefore be hereby
marked ªadvertisementº in accordance with 18 USC Section 1734tously expressed GAPDH mRNA was coamplified in the same reac-
tions and served as an internal standard. Primers were 59-CTACATG solely to indicate this fact.
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GTG-GTCAT-39 (antisense) from the published cDNA sequence (Tso Received March 7, 1996; revised April 4, 1996.
etal., 1985). P0 cDNAwas amplified with primers 59-GGTGGTGCTGT
TGCTGCTG-39 (exon 4; sense) and 59-TTGGTGCTTCGGCTGTG References
GTC-39 (exon 6; antisense) from the cDNA sequence of Lemke et al.,
(1985). PCR products (PMP22: 636 bp; GAPDH: 422 bp; P0: 188 bp) Adlkofer,K.,Martini,R.,Aguzzi, A.,Zielasek,J.,Toyka, K.V.,andSuter,
U. (1995). Hypermyelination and demyelinating peripheral neuropa-were quantified using a phosphorimager and normalized to the G/C
nucleotide content. thy in PMP-22-deficient mice. Nature Genet. 11, 274±280.
Baechner,D., Liehr,T., Hameister,H.,Altenberger, H.,Grehl,H., Suter,
Protein Analysis U., and Rautenstrauss, B. (1995). Widespread expression of the pe-
Sciatic nerve extracts were made from 100 mg frozen tissue (3 wild- ripheral myelin protein-22 gene (PMP22) in theneural andnon-neural
type and 3 transgenic rats aged 2.5 months) in 1 ml PBS (pH 7.4), 1% tissues during murine development. J. Neurosci. Res. 42, 735±741.
SDS, using a polytron homogenizer at the highest setting (10 s). The Bergoffen,J.,Scherer, J.S.S., Wang, S., Oronzi,S.M., Bone, L.J.,Paul,
homogenate was immediately boiled for 3 min and insoluble material D.L., Chen, K., Lensch, M.W., Chance, P.F., and Fischbeck, K.H.
was pelletedby centrifugation. Equal amounts of protein (10 mg)were (1993). Connexin mutations in X-linked Charcot-Marie-Tooth dis-
separated on denaturing 12% SDS-polyacrylamide gels and trans- ease. Science 262, 2039±2041.
ferred to supported nitrocellulose membranes (BA-S 85, Schleicher
Brockes, J.P., Fields, K.L., and Raff, M.C. (1979). Studies on cultured
and SchuÈ ll) by semidry electroblotting. Membranes were blocked
rat Schwann cells. I. Establishment of purified populations from cul-
with 5% nonfat dry milk (in PBS, 0.1% Tween-20) for 1 hr at room
tures of peripheral nerve. Brain Res. 165, 105±118.
temperature. Incubation with antibodies (in PBS containing 2% non-
Chance, P.F., Alderson, M.K., Leppig, K.A., Lensch, M.W., Matsu-fat dry milk) was for 1 hr, followed by a wash and 1 hr incubation with
nami, N., Smith, B., Swanson, P.D., Odelberg, S.J., Disteche, C.M.,a horseradish peroxidase-conjugated secondary antibody (Amer-
and Bird, T.D. (1993). DNA deletion associated with hereditary neu-sham),diluted1:1000 inthesame buffer. Immunoreactiveprotein was
ropathy with liability to pressure palsies. Cell 72, 143±151.detectedwith an enhanced chemiluminescence kit (ECL, Amersham)
Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNAaccording to the manufacturers instructions, using ECL-Hyperfilm
isolationbyacidguanidinium thiocyanate-phenol-chloroformextrac-(Amersham).Western blots werestrippedandreprobedwith different
tion. Anal. Biochem. 162, 156±159.antibodies. The PMP22 antipeptide antibody has been described
(Snipes et al., 1992). Antibodies against P0 (provided by J. Archelos) Dyck, P.J., Thomas, P.K., Griffin, J.W., Low, P.A., and Poduslo, J.F.,
were diluted 1:1000, antiMBP (Boehringer) 1:500, and anti-b-actin (1993). Peripheral Neuropathy, Volume 2 (Philadelphia: W.B. Saun-
(Boehringer) 1:100, respectively. For total protein analysis, 5 mg of ders Company).
nerve extract was separated on a 12% SDS-Polyacrylamid gel and Fabbretti, E., Edomi, P., Brancolini, C., and Schneider, C. (1995).
visualized by silver staining or with Coomassie Brilliant Blue R250. Apoptotic phenotype induced by overexpression of wild-type gas3/
PMP22: its relation to the demyelinating peripheral neuropathy
Schwann Cell Culture CMT1A. Genes Dev. 9, 1846±1856.
Sciatic nerves were dissected from 3 day-old rats, derived from the Ganten, D., Lindpaintner, K., Ganten, U., Peters, J., Zimmermann, F.,
mating of heterozygous PMP22-transgenic males with wild-type fe- Bader, M., andMullins, J. (1991). Transgenic rats: new animal models
males. After removal of connective tissue, nerves were dissociated in hypertension research. Hypertension 17, 843±855.
bythemethodofBrockesetal.(1979).Schwanncellsweremaintained
Garcia, C.A., Malamut,R.E.,England, J.D.,Parry, G.S.,Pentao,L., andin Dulbecco's modified Eagle's medium (DMEM), with added gluta-
Lupski, J.R. (1996). Clinical variability in two pairs of identical twinsmine, insulin, and 10% fetal calf serum. Cytosine arabinoside (1025
with the Charcot-Marie-Tooth disease type 1A duplication. Neurol-M) was added after 24 hr for 72 hr, resulting in Schwann cell cultures
ogy (in press).thatwere99%pure (S100positive). Forgrowthanalysis, 105 cellswere
Hanemann, C.O., Stoll, G., D'Urso, D., Fricke, W., Martin,J. J., Van-plated onto 10 mm coverslips (coated with poly-L-lysin plus laminin)
Broeckhoven, C., Mancardi, G.L., Bartke, I., and MuÈ ller, H.W. (1994).as described by Morgan et al. (1991). Schwann cells weremaintained
Peripheral myelin protein-22 expression inCharcot-Marie-Tooth dis-in defined medium consisting of a 1:1 mixture of DMEM and Ham's
ease type 1a sural nerve biopsies. J. Neurosci. Res. 37, 654±659.F12 medium, supplemented with BSA (30 mg/ml), dexamethasone
(38 ng/ml), insulin (5 mg/ml), progesterone (60 ng/ml), putrescine (16 Hayasaka, K.,Himoro,M.,Sato,W., Takada,G.,Uyemura,K.,Shimizu,
mg/ml), thyroxine (0.4 mg/ml), transferrin (100 mg/ml), triiodonothyro- N., Bird, T.D., Conneally, P.M., and Chance, P.F. (1993). Charcot-Ma-
nine (10 ng/ml), selenium (160 ng/ml), all purchased from Sigma rie-Tooth neuropathy type 1B is associated with mutations of myelin
Chemical Company, and supplemented with NDFB2 (10 ng/ml glial P0 gene. Nature Genet. 5, 31±34.
growth factor) and 4 mM forskolin. To determine the percentage of Hudson, L.D. (1990). Molecular biology of myelin proteins in the cen-
DNAsynthezising Schwann cells,59-bromo-deoxyuridine (BrdU) was tral and peripheral nervous system. Sem. Neurosci. 2, 483±496.
addedat10mM for24hr (Morganetal.,1991). Indirectimmunofluores-
Ionasescu, V.V. (1995)Charcot-Marie-Tooth neuropathies: from clini-cence analysis, using anti-BrdU antibodies (Boehringer) was per-
cal description to molecular genetics. Muscle Nerve 18, 257±275.formed by standard procedures, and 200±300 nuclei were counted
Ionasescu, V.V., Ionasescu, R., Searby, C., and Neahring, R. (1995).per experiment (n 5 17). The genotype of each rat was determined in
Dejerine-Sottas diseasewith de novo dominant point mutation of thea double-blinded fashion.
PMP22 gene. Neurology 45, 1766±1767.
Kagawa, T., Ikenaka, K., Inoue, Y., Kuriyama, S., Tsujii, T., Nakao, J.,Acknowledgments
Nakajima, K., Aruga, J., Okano, H., and Mikoshiba, K.. (1994). Glial
cell degeneration andhypomyelination caused by overexpression ofCorrespondence should be addressed to K.-A. N. (e-mail: nave@
sunO.urz.uni-heidelberg.de). We thank H. Krischke and C. Zgraggen myelin proteolipid protein gene. Neuron 13, 427±442.
CMT-Rat Model
1059
Kaku, D.A., Parry, G.J., Malamut, R., Lupski, J.R., and Garcia, C.A. Roa, B.B., Garcia, C.A., Pentao, L., Killian, J.M., Trask, B. J., Suter,
U., Snipes, G.J., Shooter, E.M., Patel, P.I., and Lupski, J.R. (1993b).(1993).Nerveconduction studiesinCharcot-Marie-Toothneuropathy
associated with a segmental duplication of chromosome 17. Neurol- Evidence for a recessive PMP22 point mutation in Charcot-Marie-
Tooth disease type 1A. Nature Genet. 5, 189±194.ogy 43, 1806±1808.
Kamholz, J., Shy, M., and Scherer, S. (1994). Elevated expression of Roa, B.B., Garcia, C.A., Suter, U., Kulpa, D.A., Wise, C.A., Mueller, J.,
messenger RNA for peripheral myelin protein 22 in biopsied periph- Welcher, A.A.,Snipes, G.J., Shooter,E.M., Patel, P.I., andLupski, J.R.
eral nerves of patients with Charcot-Marie-Tooth disease type 1A. (1993c). Charcot-Marie-Tooth disease type 1A: Association with a
Ann. Neurol. 36, 451±452. spontaneous point mutation in the PMP22gene. N. Engl.J. Med. 329,
96±101.Kitamura, K.M., Suzuki, M., and Uyemura, K. (1976). Purification and
partialcharacterization of two glycoproteins inbovine peripheral my- Schneider, C., King, R.M., andPhillipson,L. (1988). Genesspecifically
elin membrane. Biochim. Biophys. Acta 455, 806±816. expressed at growth arrest of mammalian cells. Cell 54, 787±793.
Lemke, G. (1988). Unwrapping the genes of myelin. Neuron 1, Skre, H. (1974). Genetic and clinical aspects of Charcot-Marie-
535±543. Tooth's disease. Clin. Genet. 6, 98±118.
Lemke, G., and Axel, R. (1985). Isolation and sequence of a cDNA Snipes, G.J., and Suter, U. (1995a). Molecular anatomy and genetics
encoding the major structural protein of peripheral myelin. Cell 40, of myelin proteins in the peripheral nervous system. J. Anat. 186,
501±508. 483±494.
Lupski, J.R., de Oca Luna, R.M., Slaugenhaupt, S., Pentao, L., Guz- Snipes,G.J., andSuter,U. (1995b).Molecularbasisofcommon hered-
zetta, V., Trask, B.J., Saucedo-Cardenas, O., Barker, D.F., Killian, itary motor and sensory neuropathies in humans and in mouse mod-
J.M.,Garcia, C.A., Chakravarti, A., andPatel, P.I. (1991).DNA duplica- els. Brain Path. 5, 233±247.
tion associated with Charcot-Marie-Tooth disease type 1A. Cell 66, Snipes, G.J., Suter U., Welcher, and A.A.,Shooter, E.M. (1992). Char-
219±232. acterization of a novel peripheral nervous system myelin protein
Lupski, J.R., Chance, P.F., and Garcia, C.A. (1993). Inherited primary (PMP-22/SR13). J. Cell. Biol. 117, 225±238.
peripheral neuropathies. JAMA 270, 2326±2330.
Spreyer, P., Kuhn, G., Hanemann, C.O., Gillen, C., Schaal, H., Kuhn,
Manfioletti, G., Ruaro, M.E., Del Sal, G., Philipson, L., and Schneider, R., Lemke, G., and MuÈ ller, H.W. (1991). Axon-regulated expression of
C. (1990). A growth arrest-specific (gas) gene codes for a membrane a Schwann cell transcript that is homologous to a ªgrowth arrest-
protein. Mol. Cell. Biol. 10, 2924±2930. specificº gene. EMBO J. 10, 3661±3668.
Matsunami, N., Smith, B., Ballard, L., Lensch, M.W., Robertson, M., Suter,U.,Welcher, A.A.,OzcelikT., Snipes,G.J., Kosaras,B.,Francke,
Albertsen, H., Hanemann, C.O., Muller, H. W., Bird, T.D., White, R., U., Billings-Gagliardi, S., Sidman, R.L., and Shooter, E.M. (1992).
and Chance, P.F. (1992). Peripheral myelin protein-22 gene maps in Trembler mousecarriesa point mutation ina myelingene. Nature 356,
theduplicationinchromosome17p11.2associatedwith Charcot-Ma- 241±244.
rie-Tooth 1A. Nature Genet. 1, 176±179.
Suter, U., Snipes, G.J., Schoener-Scott, R., Welcher, A.A., Pareek,
Morgan L., Jessen, K.R., and Mirsky, R. (1991). The effects of cyclic S., Lupski, J.R., Murphy, R.A., Shooter, E.M., and Patel, P.I. (1994).
AMP on the differentiation of cultured Schwann cells: progression Regulation of tissue-specific expression of alternative peripheral
from an early phenotype (041) to a myelin phenotype (P01, GFAP2, meyelin protein-22 (PMP22) gene transcripts by two promoters. J.
N-CAM1, NGF-receptor2) depends on growth inhibition. J. Cell Biol. Biol. Chem. 269, 1±14.
112, 457±467.
Timmerman, V., Nelis, E., Van-Hul, W., Nieuwenhuijsen, B. W., Chen,
Nave, K.-A. (1995). Neurological mousemutants: a molecular genetic K.L., Wang, S., Ben-Othman, K., Cullen, B, Leach, R.J., Hanemann,
analysis of myelin proteins. In Neuroglial Cells, H. Kettenmann and B. C.O., DeJonghe, P., Raeymaekers, P., van Ommen, G.J.B., Martin,
Ransom, eds. (New York: Oxford University Press) pp. 571±586. J.J., Mueller, H.W., Vance, J. M., Fischbeck, K.H., andVan Broeckho-
Nave, K.-A., and Boespflug-Tanguy, O. (1996). Developmental de- ven, C. (1992). The peripheral myelin protein gene PMP-22 is con-
fects ofmyelin formation: from X-linked mutations to human dysmye- tained within the Charcot-Marie-Tooth disease type 1A duplication
linating diseases. Neuroscientist 2, 33±43. Nature Genet. 1, 171±175.
Nicholson, G.A. (1991). Penetrance of the hereditary motor and sen- Tso,J.Y.,Sun, X.H.,Kao,T.H., Reece,K.S.,andWu, R.(1985). Isolation
sory neuropathy 1a mutation: assessment by nerve conduction stud- and characterization of rat and human glyceraldehyde-3-phosphate
ies. Neurology 41, 547±552. dehydrogenase cDNAs: Genomic complexity and molecular evolu-
tion of the gene. Nucleic Acids Res. 13, 2485±2502.Parmantier, E., Cabon, F., Braun, C., D'Urso, D., Mueller, H. W., and
Zalc, B. (1995). Peripheral myelin protein-22 is expressed in rat and Valentijn, L.J., Bolhuis, P.A., Zorn, I., Hoogendijk, J.E., van-den-
mouse brainand spinal cord motoneurons. Eur. J. Neurosci.7, 1080± Bosch, N., Hensels, G.W., Stanton, V.P., Housman, D.E., Fischbeck,
1088. K.H., Ross, D.A., Nicholson, G. A., Meershoek, E.J., Dauwerse, H.G.,
Van Ommen, G.J. B., Baas, F., Stanton Jr., V.P., (1992a). The periph-Patel, P.I., and Lupski, J.R. (1994). Charcot-Marie-Tooth disease: a
eral myelin gene PMP-22/GAS-3 is duplicated in Charcot-Marie-newparadigm for themechanism of inheriteddisease. Trends Genet.
Tooth disease type 1A. Nature Genet. 1, 166±170.10, 128±133.
Valentijn, L.J., Baas, F., Wolterman, R.A., Hoogendijk, J.E., van-den-Patel, P.I., Roa, B.B., Welcher, A.A., Schoener-Scott, R., Trask. B.J.,
Bosch, N.H., Zorn, I., Gabreels-Festen, A.W., de-Visser, M., and Bol-Pentao,L., Snipes,G.J., Garcia, C.A., Francke, U.,Shooter, E.M., Lup-
huis, P.A. (1992b). Identical point mutations of PMP-22 in Trembler-ski, J.R., and Suter, U. (1992). The gene for the peripheral myelin pro-
J mouse and Charcot-Marie-Tooth disease type 1A. Nature Genet. 2,tein PMP-22 is acandidate for Charcot-Marie-Toothdisease type 1A.
288±291.Nature Genet. 1, 159±165.
Welcher, A.A., Suter, U., De Leon, M.,Snipes, G.J., and Shooter, E.M.Raeymaekers,P., Timmerman,V.,Nelis, E.,De, J.P.,Hoogendijk,J.E.,
(1991). A myelin protein is encoded by the homologue of a growthBaas, F., Barker, D.F., Martin, J.J., De, V.M., Bolhuis, P.A., and Van
arrest-specific gene. Proc. Natl. Acad. Sci. USA 88, 7195±7199.Broeckhoven, C. (1991).Duplication in chromosome17p11.2 inChar-
cot-Marie-Tooth neuropathy type1a (CMT1a). The HMSNCollabora- Wise, C.A., Garcia, C.A., Davis, S.N., Heju, Z., Pentao, L., Patel, P.I.,
tive Research Group. Neuromusc. Disord. 1, 93±97. andLupski, J.R. (1993). Molecularanalysesof unrelated Charcot-Ma-
rie-Tooth (CMT) disease patients suggest a high frequency of theReadhead, C., Schneider, A., Griffiths, I., and Nave, K.-A. (1994). Pre-
CMTIA duplication. Am. J. Hum. Genet. 53, 853±863mature arrest of myelin formation in transgenic mice with increased
dosage of the proteolipid protein gene. Neuron 12, 583±595. Yoshikawa, H., Nishimura T., Nakatsuji Y., Fujimura, H., Himoro, M.,
Hayasaka, K.,Sakoda,S., andYanagihara,T. (1994).Elevatedexpres-Roa, B.B., Dyck, P.J., Marks, H.G., Chance, P.F., and Lupski, J.R.
(1993a). Dejerine-Sottas syndrome associated with point mutation sion of messenger RNA for peripheral myelin protein 22 in biopsied
peripheral nerves of patients with Charcot-Marie-Tooth disease typein the peripheral myelin protein 22 (PMP22) gene. Nature Genet. 5,
269±272. 1A. Ann. Neurol. 35, 445±450.
Neuron
1060
Zoidl, G., Blass-Kampmann, S., D'Urso, D., Schmalenbach, C., and
MuÈ ller, H.W. (1995). Retroviral-mediated gene transfer of the periph-
eral myelin protein PMP22 in Schwann cells: modulation of cell
growth. EMBO J. 14, 1122±1128.
